Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 1/20 | 0.31 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.31 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.31 |
| ▸ | BUB1 | O43683 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4820283 | 0.83 | BMPR1B (0.32) | — | |
| SCHEMBL8482964 | 0.75 | AXL (0.31) | BUB1 | |
| SCHEMBL3584083 | 0.75 | PRKCI (0.31) | BUB1 | |
| SCHEMBL3581102 | 0.75 | NCF1 (0.32) | BUB1 | |
| SCHEMBL15308536 | 0.75 | CCR1 (0.35) | ADRA2AADRA2CADRA1DADRA1AADRA1B | |
| SCHEMBL30507904 | 0.75 | PRKCI (0.31) | BUB1 | |
| SCHEMBL18739049 | 0.75 | BUB1 (0.30) | BUB1 | |
| SCHEMBL16664914 | 0.73 | PARP1 (0.30) | — | |
| SCHEMBL15306530 | 0.72 | KIT (0.31) | BUB1 | |
| SCHEMBL16019537 | 0.71 | BUB1 (0.33) | BUB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160368899-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-12-22 | — | — | US | disclosed |
| WO-2015058031-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160368899-A1 | DNA-PK INHIBITORS | POLK, DTYMK, DCK | ADRA2A 4043/4885ADRA2C 3412/4885ADRA1D 3743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.